Trevi Therapeutics (TRVI) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)
March 19, 2025 7:22 AM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).
The analyst comments "We remain Strong Buy rated on TRVI following 4Q24 earnings. Our bullish thesis that Haduvio could potentially become the go-to... More
